Glycomimetics Inc (GLYC): Helen M. Thackray , VP Clinical Development, CMO of Glycomimetics Inc sold 2,000 shares on Jul 20, 2016. The Insider selling transaction was reported by the company on Jul 21, 2016 to the Securities and Exchange Commission. The shares were sold at $8.00 per share for a total value of $16,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 6, 2016, Helen M. Thackray (VP Clinical Development, CMO) sold 22,000 shares at $7.03 per share price.On Mar 7, 2016, Mark Alan Goldberg (director) purchased 10,397 shares at $4.77 per share price.Also, On Nov 18, 2015, Peter J Barris (10% owner) sold 452 shares at $6.91 per share price.On Nov 18, 2015, Scott D Sandell (10% owner) sold 452 shares at $6.91 per share price.
GlycoMimetics Inc: On Wednesday, Jul 20, 2016 heightened volatility was witnessed in GlycoMimetics Inc which led to swings in the share price. The shares opened for trading at $7.96 and hit $8.15 on the upside , eventually ending the session at $8.1, with a gain of 2.53% or 0.2 points. The heightened volatility saw the trading volume jump to 35,776 shares. The 52-week high of the share price is $9.25 and the company has a market cap of $157 M . The 52-week low of the share price is at $3.7.
GlycoMimetics Inc. (GlycoMimetics) is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs to address medical needs. The Company’s pipeline includes GMI-1070 (Rivipansel) GMI-1271 GMI-1359 (E-selectin and CXCR4 antagonist) GMI-1051 and Galectin inhibitors. The Company developing rivipansel to treat VOC (vaso-occlusive crisis) with the goal of reducing duration of VOC episodes length of hospital stay and use of opioid analgesics for pain management. The Company is developing GMI-1271 a specific E-selectin antagonist to be used in combination with chemotherapy to treat AML (acute myeloid leukemia) and other hematologic cancers. GMI-1359 simultaneously inhibits both E-selectin and CXCR4 for use in the treatment of cancers with bone marrow involvement such as myeloma. GMI-1051 is an antagonist of two pseudomonas virulence factors PA-IL and PA-IIL.